Matches in Nanopublications for { ?s ?p "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- NP760173.RAi8h0DPo7AFUkruUTUERnjPxr5d4yd4B7RDttjC-uuM4130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP760173.RAi8h0DPo7AFUkruUTUERnjPxr5d4yd4B7RDttjC-uuM4130_provenance.
- NP877132.RAlowM-8Jichokg-SmHC3hDXXjAYnR0py085L0FLfd_SI130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP877132.RAlowM-8Jichokg-SmHC3hDXXjAYnR0py085L0FLfd_SI130_provenance.
- assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP283261.RAz_mXIorQknqhwN9FcEQHiGPD3QuG4833paA7LrBI5PM130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP283261.RAz_mXIorQknqhwN9FcEQHiGPD3QuG4833paA7LrBI5PM130_provenance.
- NP304190.RAj7JyCLmNHQGqIkBEGMa4x3J44-FR8VfHbmdXzQpfkq4130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP304190.RAj7JyCLmNHQGqIkBEGMa4x3J44-FR8VfHbmdXzQpfkq4130_provenance.
- NP471658.RAqbaasTDaAbQ0RQeiibBE7zTe2KE4uS5Ia3hpJ3okJ1M130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP471658.RAqbaasTDaAbQ0RQeiibBE7zTe2KE4uS5Ia3hpJ3okJ1M130_provenance.
- NP404999.RASkUjSWJk7fxTCGNJS12Svs3MY7rVZGLVhPT7gOWpqE4130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP404999.RASkUjSWJk7fxTCGNJS12Svs3MY7rVZGLVhPT7gOWpqE4130_provenance.
- NP486113.RAjI-M9cruniokm1OHKO_n-v2uinlnZ8Ccb4dWFLn0XRk130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP486113.RAjI-M9cruniokm1OHKO_n-v2uinlnZ8Ccb4dWFLn0XRk130_provenance.
- NP356571.RAeV-ynShxi9YvmlMIETUvOZ3VVdSImznrg0SBTK1MpmA130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP356571.RAeV-ynShxi9YvmlMIETUvOZ3VVdSImznrg0SBTK1MpmA130_provenance.
- assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP471251.RA_biu-bYGq_qp5_ysCrnfXdc0sRpqOwt59-OYRyxv21U130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP471251.RA_biu-bYGq_qp5_ysCrnfXdc0sRpqOwt59-OYRyxv21U130_provenance.
- NP864965.RAY4IpOkwITptOksBpjpghOOPxA1uO0npA7393K4ymF-k130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP864965.RAY4IpOkwITptOksBpjpghOOPxA1uO0npA7393K4ymF-k130_provenance.
- NP556016.RAz2CcbXl4sJd0AsGJTzy6M4HAtX313tPXpMTVIkAjm9A130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP556016.RAz2CcbXl4sJd0AsGJTzy6M4HAtX313tPXpMTVIkAjm9A130_provenance.
- NP629091.RA7iNQ9pGNGpgqtLTFgsKkUnHL_dhZDf42omWfHt40B3A130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP629091.RA7iNQ9pGNGpgqtLTFgsKkUnHL_dhZDf42omWfHt40B3A130_provenance.
- NP625198.RAXcBbFATPWtoBnZ5Ly-ze2t2rRLK8b27DJMyQF-PeN7o130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625198.RAXcBbFATPWtoBnZ5Ly-ze2t2rRLK8b27DJMyQF-PeN7o130_provenance.
- NP622742.RAV5yToI-j9imig5jyv1eWJTPZZDxNQkmSdmwy5c0kLeg130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622742.RAV5yToI-j9imig5jyv1eWJTPZZDxNQkmSdmwy5c0kLeg130_provenance.
- assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1107264.RAVrnWlz3nZtshCl8g_8FU-caUwy7e2vmMwzgSSiiqESE130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1107264.RAVrnWlz3nZtshCl8g_8FU-caUwy7e2vmMwzgSSiiqESE130_provenance.
- NP621399.RAAULfT8JBEV6MgnxywhSAtgGQJUROkbhsAUJbd-UQGVQ130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP621399.RAAULfT8JBEV6MgnxywhSAtgGQJUROkbhsAUJbd-UQGVQ130_provenance.
- NP683261.RAGDHPPl0lAvhXy_Mwx5PIgSqY9Fd4zJLk6UdrkJdVyHk130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP683261.RAGDHPPl0lAvhXy_Mwx5PIgSqY9Fd4zJLk6UdrkJdVyHk130_provenance.
- NP624058.RAvSWLwmCDItXvzSZZ_RQSD6Mt2wIqGYtocepNSZMWva8130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624058.RAvSWLwmCDItXvzSZZ_RQSD6Mt2wIqGYtocepNSZMWva8130_provenance.
- NP923467.RAJRVw3PUpDNU2b91pKnWL_ubJqK1tl8hWlWYjaSotvu8130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP923467.RAJRVw3PUpDNU2b91pKnWL_ubJqK1tl8hWlWYjaSotvu8130_provenance.
- NP1107267.RAvXM-yIZvq8RSLVFnOpN17On5grYZu2CkZDPIyNnF7ak130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1107267.RAvXM-yIZvq8RSLVFnOpN17On5grYZu2CkZDPIyNnF7ak130_provenance.
- NP1107268.RAsYRRHNlpwL3uZL2ZHW7HorhVXl0RSI1-d1uugJnwf9o130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1107268.RAsYRRHNlpwL3uZL2ZHW7HorhVXl0RSI1-d1uugJnwf9o130_provenance.
- NP1107269.RAjkLW8QPc0sGMPdZJqe_JLdSYarjob2nJIPc9v_S_tUk130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1107269.RAjkLW8QPc0sGMPdZJqe_JLdSYarjob2nJIPc9v_S_tUk130_provenance.
- NP1107270.RAm-y2XIvk3Xx_Ex_aAtA-u06936Fr03sG8n0rbssmK0M130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1107270.RAm-y2XIvk3Xx_Ex_aAtA-u06936Fr03sG8n0rbssmK0M130_provenance.
- NP232357.RA_QZOFRfhirtmnqD3JxySaXCnSoX5zp7mxRfN8NEP5Sk130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP232357.RA_QZOFRfhirtmnqD3JxySaXCnSoX5zp7mxRfN8NEP5Sk130_provenance.
- NP773709.RAJObMiFhWnqltkBTSJc094OFPvRPqKJUid0QKzsySdx4130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773709.RAJObMiFhWnqltkBTSJc094OFPvRPqKJUid0QKzsySdx4130_provenance.
- NP892614.RAGopWUYroQHc91NLTGWv3CyDYYvPIs5tBgiHhihR1jDE130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP892614.RAGopWUYroQHc91NLTGWv3CyDYYvPIs5tBgiHhihR1jDE130_provenance.
- NP1107265.RAEAxYdozwxeXjxRI7vDSogDXguypXPQ_zDFgxLG5zBfo130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1107265.RAEAxYdozwxeXjxRI7vDSogDXguypXPQ_zDFgxLG5zBfo130_provenance.
- NP1107266.RAGJ2cjbLwWsJaeYfKuZhxWs_qIExiJnXX5YAGICD-ZRc130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1107266.RAGJ2cjbLwWsJaeYfKuZhxWs_qIExiJnXX5YAGICD-ZRc130_provenance.
- NP1107263.RA72OhIR-fRGAe4jfrSUxLK_h2zkdpGMETsj_5dmtLxfI130_assertion description "[HIF-1 is also activated in cancer cells by tumor suppressor (e.g., VHL) loss of function and oncogene gain of function (leading to PI3K/AKT/mTOR activity) and mediates metabolic alterations that drive cancer progression and resistance to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1107263.RA72OhIR-fRGAe4jfrSUxLK_h2zkdpGMETsj_5dmtLxfI130_provenance.